Study links anemia drugs to fatal blood clots

11/11/2009 | U.S. News & World Report

Researchers found that cancer patients who received erythropoiesis-stimulating agents, such as Procrit and Aranesp, to prevent chemotherapy-related anemia were more likely to develop deep vein thrombosis or pulmonary embolism than those who did not receive the drugs. The results raise concerns regarding the approval process and postmarketing research conducted to ensure long-term safety of such drugs, the lead researcher said.

View Full Article in:

U.S. News & World Report

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Payer Marketing
Avalere Health
Washington, DC
Chief Quality Officer
UnityPoint Clinic
Des Moines, ID
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX
The Pew Charitable Trusts
Director, Antibiotics and Innovation Project
Washington, DC
Senior Officer, Drugs and Medical Devices
The Pew Charitable Trusts
Washington, DC